Drug Database
Back to search

Poland· PL-100370188

Idarubicin Accord

A idarubicin product containing idarubicini hydrochloridum, registered in Poland by Accord Healthcare Polska Sp. z o.o.. The same ATC class is registered in 17 of our 19 countries.

ATC L01DB06

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedIdarubicin AccordATCL01DB06REGISTER NO.PL-100370188PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about idarubicini hydrochloridumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Idarubicin is registered in 17 of 19 countries.

Countries holding a registration under ATC L01DB06 (idarubicin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose
Search idarubicin products by name

Idarubicin · ATC L01DB06

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Idarubicini hydrochloridum
Manufacturer
Accord Healthcare Polska Sp. z o.o.
Country
Poland (PL)
ATC code
L01DB06
ATC class
Idarubicin
Defined daily dose
6 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909991331016

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

435 interactions on record for idarubicin.

Graded by severity as the source publishes them — 98 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check idarubicin against other medicinesHow interaction checks work

Idarubicin · interactions on record

435 records

  • 98 severe
  • 328 moderate
  • 9 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • QuinidineC01BA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Idarubicin in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All idarubicin products

Authorised across Europe · EMA

The same active substance is authorised in 27 EEA countries. Names it is sold under:

  • Austria · Idarubicin Ebewe, Idarubicin Hexal
  • Belgium · Zavedos
  • Bulgaria · Заведос
  • Cyprus · Zavedos
  • Czechia · Zavedos
  • Germany · Idarubicin Hexal, Idarubicin Hikma
  • Denmark · Zavedos
  • Spain · Idarubicina Sandoz, Zavedos
  • Finland · Idarubicin Accord, Zavedos
  • France · Idarubicine Accord, Zavedos
  • United Kingdom (Northern Ireland) · Idarubicin Accord Healthcare, Idarubicin Sandoz
  • Greece · Zacorist, Zavedos
  • Croatia · Zavedos
  • Hungary · Zavedos
  • Ireland · Zavedos
  • Iceland · Zavedos
  • Italy · Zavedos
  • Lithuania · Zavedos
  • Luxembourg · Zavedos
  • Latvia · Zavedos
  • Netherlands · Zavedos
  • Norway · Zavedos
  • Portugal · Idarrubicina Accord, Idarrubicina Azevedos
  • Romania · Zavedos
  • Sweden · Zavedos
  • Slovenia · Zavedos
  • Slovakia · Zavedos

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/513527e9-0174-475a-983e-69cb45253768
GET /v1/drugs/513527e9-0174-475a-983e-69cb45253768?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań",
  "source": "urpl",
  "strength": "10 mg/10 ml",
  "packaging": "05909991331016 ¦ Lz ¦ 122175\n1 fiol. 10 ml",
  "substance": "Idarubicini hydrochloridum 10mg/10ml",
  "common_name": "Idarubicini hydrochloridum",
  "pl_product_id": "100370188",
  "pozwolenie_nr": "23991",
  "auth_procedure": "MRP",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about idarubicin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console